Scienture HoldingsSCNX -3.56%47 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates SCNX with a GF Score™ of 47/100 and a GF Value™ of $0.35 (Fairly Valued). The stock has 6 warning signs investors should review. Among 453 Healthcare Providers & Services companies, Scienture Holdings ranks worse than 220750.33% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Scienture Holdings's
Operating Income
for the
three
months ended in Mar. 2026 was $-3.51 Mil. Scienture Holdings's Interest Expense for the
three
months ended in Mar. 2026 was $-0.04 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Scienture Holdings's Interest Coverage or its related term are showing as below:
SCNX's Interest Coverage is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 7.98 * Ranked among companies with meaningful Interest Coverage only.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Scienture Holdings Interest Coverage Related Terms
Scienture Holdings Interest Coverage Historical Data
* Premium members only.
The historical data trend for Scienture Holdings's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SCNX vs WGRX, HEWA, BLMH: Interest Coverage Comparison
For the Pharmaceutical Retailers subindustry, Scienture Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scienture Holdings Interest Coverage vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Scienture Holdings's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Scienture Holdings's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Scienture Holdings did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Scienture Holdings (SCNX) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Scienture Holdings and its competitors. According to the industry distribution chart, Scienture Holdings ranks #999999 out of 453 companies in the Healthcare Providers & Services industry.
Is Scienture Holdings' Interest Coverage too high?
Scienture Holdings' current Interest Coverage is 0 (At Loss). Based on the distribution chart, Scienture Holdings ranks #999999 out of 453 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Scienture Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Scienture Holdings' Interest Coverage compare to WGRX and HEWA?
According to the Healthcare Providers & Services industry distribution chart, Scienture Holdings ranks #999999 out of 453 companies for Interest Coverage. This places Scienture Holdings in the lower half of its industry. The industry median Interest Coverage is 7.98. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Healthcare Providers & Services company?
The median Interest Coverage among Healthcare Providers & Services companies is 7.98, based on 453 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Scienture Holdings and its competitors. For the Healthcare Providers & Services industry, the median Interest Coverage is 7.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scienture Holdings's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scienture Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scienture Holdings (SCNX) is currently considered Fairly Valued. The stock's GF Value™ is $0.35, compared to a current price of $0.37 — trading 6.3% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Scienture Holdings' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Scienture Holdings (SCNX), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scienture Holdings (SCNX) Overvalued in 2026?
Based on GuruFocus' analysis, Scienture Holdings stock appears to be overvalued.
The current stock price of $0.37 is trading 6.3% above its estimated GF Value™ of $0.35.
GuruFocus considers Scienture Holdings to be Fairly Valued.
Key valuation signals for SCNX:
Interest Coverage: 0 (At Loss)
GF Value™: $0.35 vs. price of $0.37 (6.3% above fair value)
No single metric tells the full story. See the SCNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
47GF Score
Get the complete analysis for SCNX
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNX has been successfully added to your 
